# In elderly patients over 90 years old with acute kidney injury post-infection, does prolonged intermittent renal replacement therapy improve outcomes compared to standard therapy?

Submission date	Recruitment status	Prospectively registered
18/08/2024	No longer recruiting	<pre>Protocol</pre>
Registration date	Overall study status	Statistical analysis plan
19/08/2024	Completed	Results
Last Edited	Condition category	Individual participant data
19/08/2024	Urological and Genital Diseases	<ul><li>Record updated in last year</li></ul>

## Plain English summary of protocol

Background and study aims

This study investigates the effectiveness of a specialized treatment called Prolonged Intermittent Renal Replacement Therapy (PIRRT) in elderly patients over 90 years old who develop acute kidney injury (AKI) following an infection. The goal is to understand how well this treatment works in such elderly patients and to identify factors that affect their survival.

## Who can participate?

The study was conducted on elderly patients aged 90 and above who developed AKI after an infection and were treated at the China-Japan Friendship Hospital.

# What does the study involve?

We collected and analyzed medical data from patients treated with PIRRT over the past five years. The study focuses on their treatment outcomes and the factors that may influence their survival.

What are the possible benefits and risks of participating?

The findings suggest that nearly half of the elderly patients survived for more than 90 days after receiving PIRRT, indicating that this treatment can be effective. However, patients with pre-existing chronic kidney disease, certain complications like low calcium levels, rapid heart rates, or high potassium levels had a poorer prognosis.

Where is the study run from? China-Japan Friendship Hospital (China)

When is the study starting and how long is it expected to run for? June 2019 to May 2024

Who is funding the study? This research is funded by the National Natural Science Foundation (China) (82304363)

Who is the main contact?
Dr Zheng Zhang, 88dahongmao88@sina.com

# **Contact information**

## Type(s)

Public, Scientific, Principal investigator

#### Contact name

Dr Zheng Zhang

#### **ORCID ID**

https://orcid.org/0000-0002-8480-1555

#### Contact details

No. 2, Yinghua East Street, Chaoyang District Beijing China 100029 +86 18811414199 88dahongmao88@sina.com

# Additional identifiers

#### Clinical Trials Information System (CTIS)

Nil known

# ClinicalTrials.gov (NCT)

Nil known

#### Protocol serial number

Nil known

# Study information

#### Scientific Title

Prolonged intermittent renal replacement therapy in elderly patients over 90 years old with acute kidney injury post-infection: a retrospective cohort study

# Study objectives

Prolonged intermittent renal replacement therapy (PIRRT) improves clinical outcomes compared to standard therapy in elderly patients over 90 with acute kidney injury following infection.

# Ethics approval required

Ethics approval required

#### Ethics approval(s)

approved 27/09/2016, China-japan Friendship Hospital Clinical Research Ethics Committee (2 Yinghua East Street, Chaoyang District, Beijing, 100029, China; +86 10 66937166; zryyec@126.com), ref: S2016-100-01

## Study design

Observational single-center retrospective cohort study

### Primary study design

Observational

#### Study type(s)

**Efficacy** 

#### Health condition(s) or problem(s) studied

Renal replacement therapy for acute kidney injury after infection in elderly patients

#### **Interventions**

Using prolonged intermittent renal replacement therapy (PIRRT), observe patient survival time and explore the correlation between clinical factors and prognosis.

#### Intervention Type

Procedure/Surgery

## Primary outcome(s)

Measured using patient records:

- 1. Age at baseline
- 2. Gender at baseline
- 3. Systolic Blood Pressure: Average all measurements taken from baseline over the next 3 days
- 4. Diastolic Blood Pressure: Average all measurements taken from baseline over the next 3 days
- 5. Heart Rate: Average all measurements taken from baseline over the next 3 days
- 6. Creatinine at baseline
- 7. Estimated Glomerular Filtration Rate at baseline
- 8. Urea at baseline
- 9. Sodium at baseline
- 10. Potassium at baseline
- 11. Calcium at baseline
- 12. Phosphorus at baseline
- 13. B-type Natriuretic Peptide at baseline
- 14. Hemoglobin at baseline
- 15. White Blood Cell Count at baseline
- 16. Neutrophil Count at baseline
- 17. Lymphocyte Count at baseline
- 18. Platelet Count at baseline
- 19. C-Reactive Protein at baseline
- 20. Procalcitonin at baseline
- 21. Prothrombin Time at baseline
- 22. Activated Partial Thromboplastin Time at baseline
- 23. SOFA Score at baseline
- 24. APACHE II Score at baseline

# Key secondary outcome(s))

There are no secondary outcome measures

## Completion date

01/05/2024

# **Eligibility**

# Key inclusion criteria

- 1. Patients over 90 years old
- 2. Acute kidney injury (AKI) due to infection
- 3. Received Prolonged Intermittent Renal Replacement Therapy (PIRRT)

# Participant type(s)

**Patient** 

# Healthy volunteers allowed

No

# Age group

Adult

# Lower age limit

90 years

# Upper age limit

150 years

#### Sex

All

# Total final enrolment

20

# Key exclusion criteria

Does not meet inclusion criteria

#### Date of first enrolment

01/06/2019

#### Date of final enrolment

01/05/2024

# **Locations**

#### Countries of recruitment

China

Study participating centre
China-Japan Friendship Hospital
2 Yinghua East Street, Chaoyang District
Beijing
China
100029

# Sponsor information

#### Organisation

China-Japan Friendship Hospital

#### **ROR**

https://ror.org/037cjxp13

# Funder(s)

# Funder type

Government

#### **Funder Name**

National Natural Science Foundation of China

#### Alternative Name(s)

Chinese National Science Foundation, Natural Science Foundation of China, National Science Foundation of China, NNSF of China, NSF of China, National Nature Science Foundation of China, Guójiā Zìrán Kēxué Jījīn Wěiyuánhuì, , NSFC, NNSF, NNSFC

## **Funding Body Type**

Government organisation

# **Funding Body Subtype**

National government

#### Location

China

# **Results and Publications**

# Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request, 88dahongmao88@sina.com

# IPD sharing plan summary

Available on request

**Study outputs** 

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet
Participant information sheet
11/11/2025 No Yes